Sun Pharmaceutical has won US approval to buy Ranbaxy Laboratories on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.
In April last year, Sun Pharmaceutical had agreed to buy generic drug maker Ranbaxy from its owner Japan’s Daiichi Sankyo Co for $3.2 billion.
The Federal Trade Commission said it would allow the transaction if Ranbaxy sold its interests in generic minocycline tablets and capsules to generic maker Torrent Pharmaceuticals Ltd, which is also based in India.
According to this order, the drugs that Ranbaxy will have to divest include Terlipresslin, Rosuvastatin and Leuprorelin.
Sun Pharma will have to either divest its molecules or ask Ranbaxy to divest molecules held by it in other drug areas.
The FTC said the proposed acquisition would reduce the number of future suppliers in the markets for generic minocycline tablets.
Full Content: The Hindu
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI